tralokinumab

Action and Spectrum

Actions and Spectrum: 

tralokinumab is a medication that belongs to a class of drugs called monoclonal antibodies. It is used to treat moderate-to-severe eczema in adults who have not responded well to other treatments. 

tralokinumab works by blocking a protein called interleukin-13 (IL-13), which is known to play a role in the development of eczema. 

Drug Interaction

Adverse Reaction

Frequency Defined  

>10%  

Upper respiratory tract infections (30%)  

Injection site reactions (11.1%)  

Upper respiratory tract infections (23.8%)  

Conjunctivitis (13.6%)  

1-10%  

Eosinophilia (1.4%)  

Injection site reactions (7.4%)  

Conjunctivitis (7.5%)  

Black Box Warning

Contraindication / Caution

Contraindication/Caution: 

• Hypersensitivity: tralokinumab should not be used in individuals who have a known hypersensitivity to the medication or any of its ingredients. 
• Active Infection: tralokinumab should be used with caution in individuals with an active infection, as it may suppress the immune system and increase the risk of infection. 
• Vaccinations: Individuals who receive tralokinumab should avoid live vaccines and should consult with their healthcare provider before receiving any other vaccines. 
• Pregnancy and breastfeeding: The safety of tralokinumab in pregnant and breastfeeding women has not been established. 

Pregnancy / Lactation

Pregnancy warnings:     

Pregnancy category: N/A 

Lactation: Excreted into human milk is unknown 

Pregnancy Categories:         

Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester. 

Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.   

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology:  

tralokinumab is a medication used to treat certain inflammatory conditions, such as moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. 

Pharmacodynamics: 

tralokinumab works by targeting and blocking interleukin-13 (IL-13), a protein that plays a role in promoting inflammation and immune responses in the body. By blocking the activity of IL-13, tralokinumab helps to reduce the inflammation and symptoms associated with atopic dermatitis. 

Pharmacokinetics: 

Absorption  

tralokinumab is administered as an injection into the skin, and the absorption of the drug into the bloodstream is slow and steady. The maximum serum concentration is achieved approximately 7 to 9 days after the first injection. The bioavailability of tralokinumab is estimated to be approximately 68% following subcutaneous injection.  

Distribution  

tralokinumab is distributed throughout the body after absorption and binds to the interleukin-13 (IL-13) cytokine in the blood, thereby preventing it from binding to its receptor and triggering an inflammatory response. The volume of distribution is approximately 7.4 L.  

Metabolism  

tralokinumab is metabolized by proteolytic cleavage into smaller peptides and amino acids. However, the metabolism of tralokinumab is not fully understood, and it is likely that the majority of the drug is eliminated unchanged.  

Elimination and Excretion  

tralokinumab is primarily eliminated through the kidneys, with approximately 60% of the drug being excreted in the urine and 40% in the feces.

Adminstartion

Administration:  

tralokinumab is a medication that is administered by injection and is used to treat moderate to severe atopic dermatitis in adults who have not responded well to other treatments. 

tralokinumab injections are typically administered by a healthcare provider in a medical setting such as a doctor’s office or clinic. The medication is injected under the skin (subcutaneously) in the upper arm, thigh, or abdomen. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: tralokinumab 

Why do we use tralokinumab? 

tralokinumab is a medication that is used to treat moderate to severe atopic dermatitis in adults who have not responded well to other treatments. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition that can cause dry, itchy, and inflamed skin. 

tralokinumab works by blocking a specific protein called interleukin-13 (IL-13), which is involved in the inflammatory process that contributes to atopic dermatitis. By reducing the activity of IL-13, tralokinumab helps to decrease inflammation and relieve the symptoms of atopic dermatitis.